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Abstract
Reduced calorie intake is a religious and medical practice known since very old times, 
but its direct influence on life span in all organisms, included humans, has been dem-
onstrated in the modern era. Not only periodic fasting, but also natural or synthetic 
compounds that mimic this phenomenon are growing to slow aging and the onset of 
chronic morbidities. Resveratrol (RSV), a plant polyphenol, is an elixir of longevity for 
simple organisms and preclinical rodent models even if a beneficial role in humans is still 
debated. Its main rejuvenating mechanism copes with the activation of specific longevity 
genes called sirtuins. Among seven known mammalian sirtuins, sirtuin 1 is the most 
studied. This pleiotropic nicotinamide adenine dinucleotide (NAD)-based deacetylase 
maintains longevity by removing acetyl group in nuclear histones, transcription factors, 
and other DNA repairing proteins. Actually, an exciting challenge is to discover and test 
novel sirtuin 1 activators to extend life span and to treat age-associated disabilities. This 
chapter updates on the antiaging effect of RSV and sirtuin 1 activators in experimental 
animals and in humans. Finally, pros and cons on RSV analogues and sirtuin 1 activa-
tors tested in preclinical and clinical trials to hamper neurological deficit, cardiovascular 
complications, diabetes, bone and muscle deterioration, and cancer are discussed.
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1. Introduction
The increase in average life expectancy is a global consequence of sanitary welfare, proper 
nutrition, and healthy life style [1, 2], but unfortunately, longevity is linked to the onset of 
chronic irreversible diseases like neurological decline, cardiovascular damage, bone and 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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muscle frailty, diabetes, and metabolic diseases with high economic and social costs [3–5]. 
Specific international clinical objectives are to maintain a “healthy aging” defined by World 
Health Organization (WHO) as the “functional ability that enables wellbeing in old age” by 
firstly preserving the quality of life together with its duration [6, 7]. Besides unchangeable 
genetic background, in this context, great credit is due to the quality but also the quantity of 
dietary nutrients [8–10].
Historically, since fifth century BC, the famous Greek physician Hippocrates declared that 
fasting was the best practice to block sickness progression, and, on the contrary, too much 
feeding gave rise to a disease. This old and simple medical concept, i.e., caloric restriction 
without malnutrition, has maintained for centuries but without a direct impact on life exten-
sion. Only in modern times since early 1930s, a pioneering Mc Cay discovery confirmed 
that undernutrition caused prolonged life span in laboratory rats [11]. By 2000s, Longo and 
coworkers systematically studied dietary restriction as a therapy for slowing aging and 
related diseases in human settings [12–15]. Periodic reduction of dietary calorie intake or 
an intermittent fasting, under medical control, appears alternative tools to pharmacology to 
delay the onset of aging comorbidities, like metabolic diseases, and to improve health out-
comes [16–19]. “Geroscience,” a definition coined by Burch et al. [20], identifies the branch 
of aging biology aimed to reduce human frailty and the impact of associated chronic dis-
eases. However, considering the difference in the duration of life between lower organisms 
versus humans, to fill this gap, caloric limitation has been used also in nonhuman primates 
like monkeys. Anyway, significant translational value has been attributed to dietary studies 
in short-life animals versus nonhuman primates and humans that enhanced their life span 
under reduced nutrients intake.
This chapter is focused on a natural dietary polyphenol, resveratrol (RSV), able to mimic 
calorie restriction and to prolong life duration in simple organisms and experimental animal 
models, but controversial in humans [21, 22]. RSV has been firstly identified as a modulator 
of conserved survival genes family called sirtuins [23]. Sirtuins, crucial modulators of life 
span extension and metabolism, have been firstly discovered by Guarente team as product 
of silent information regulator 2 (Sir 2) gene in yeast, Saccharomyces cerevisiae [24], worm, 
Caenorhabditis elegans, and fly fruit, Drosophila melanogaster [25]. In mammals, among seven 
known members, sirtuin 1 (SIRT1) enzyme was most beneficial against aging by mimicking 
calorie reduction [26, 27]. Moreover, other natural or synthetic compounds, more effective 
than RSV, like stimulate molecular longevity pathways via SIRT1 or pan-sirtuin activation, 
are currently under study [28–30]. Therefore, here major attention has been focused on new-
est preclinical experimental studies on laboratory animals, mainly rodents, and clinical trials 
based on RSV and other SIRT1 activators published over last 10 years. Due to the impressive 
wide scientific literature on longevity, we select only more recent articles or reviews and 
apologize in advance for unintentional omissions. We believe that a primary scope of this 
chapter is to steer readers, even if not expert in the field, to study in detail if interested, the 
newest antiaging therapeutic perspectives. Intriguingly, we stressed on the role of SIRT1 acti-
vators in cancer but a dichotomy exists based on specific type of cancer and clinical outcome. 
Indeed, SIRT1 activators (STACs) that will promote benefits in selected tumors may obtain 
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opposite detrimental effects in others. Therefore, to date, particular caution must be taken in 
the pharmacological use of SIRT1 modulators in oncology. So best understanding on SIRT1 
activation and maintenance by specific modulators is essential to fight age-derived inevitable 
disorders.
2. Sirtuin 1 history
The history of sirtuin family (silent information regulator 2—Sir 2) as antiaging proteins 
started in yeast, Saccharomyces cerevisiae, where they prolonged life span and regulated the 
number of replications from a mother cell [31]. Later, it was demonstrated in yeast that Sir 
2 was further able to block the formation of extrachromosomal DNA linked to aging and 
genetic “toxicity.” Indeed, an excess of Sir 2 gene ameliorated reproductive cycle and sus-
tained longevity in yeast budding [32]. Moreover, sirtuins were able to influence longevity 
in other lower organisms like worms, Caenorhabditis elegans [33], and dose-dependently in 
fruit fly, Drosophila melanogaster [34, 35]. Guarente team in 2000 demonstrated that the main 
action of sirtuins was to remove, as deacetylase enzymes, acetyl groups from specific lysine 
sites in nuclear histones, so allowing DNA silencing and chromosome stability [36]. This 
peculiar role is basic for an epigenetic regulation of DNA and telomere health and stabiliza-
tion. Besides on class III DNA histones, sirtuin deacetylation activity has been extended to a 
plethora of other nonhistone proteins, transcription factors, and cytoplasmic proteins, which, 
by this posttranslational event, changed their structure and consequently function or signal-
ing [37]. Recently, sirtuins have been considered not only deacetylases but also able to per-
form other posttranslational changes in their targets and for this reason defined “deacylases” 
[38]. Moreover, for their enzymatic activity, sirtuins used nicotinamide dinucleotide (NAD+) 
as a specific substrate, so their role has been related to NAD+ availability in the cell and to 
the NAD+/NADH ratio. In particular, it is known that during dietary caloric limitation and 
regular physical exercise, abundant NAD+ is produced and sirtuins are more active. There are 
two different ways to produce NAD+: one ex novo and another by conversion of nicotinamide 
(NAM) into nicotinamide mononucleotide (NMN) then charged with adenine nucleotide to 
become NAD. For vertebrates, the limiting enzyme necessary for the final step in the NAD 
synthesis is nicotinamide phosphoribosyltransferase (NAMPT) that is regulated by circadian 
rhythm regulator and clock genes (CLOCK and BMALI) [39]. The strict connection between 
NAD+ availability and sirtuin activity has been recently demonstrated and implied that com-
petition for NAD+ substrate by different enzymes may affect sirtuin level, so contributing 
to age-associated diseases in mice [40–42]. In particular, NAMPT-mediated NAD synthesis 
is associated to the transcription of circadian-regulated genes and sirtuin in metabolically 
active tissues [43]. However, another crucial step in the long sirtuin history was the character-
ization of mammalian sirtuins, seven different isoforms (sirtuin 1–7) [44]. SIRT1 is the most 
studied nuclear member, pleiotropic transcriptional factor that drives many cellular activities, 
like energy metabolism, cell survival, DNA stability, inflammation, and circadian rhythms 
[45, 46]. SIRT1 is involved not only in deacetylation of a specific histone but in complex chemi-
cal reactions for different pathways involved in metabolism, like target of rapamycin (mTOR) 
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[47], insulin signaling [48], and forkhead box O (FOXO) [49] (Figure 1). Moreover, different 
mice overexpressing SIRT1 have been characterized that presented better metabolism, less 
inflammation, and cancer but a sex-dependent longevity (longer mean life span in males vs 
females) [50]. In these last 5 years, the involvement of SIRT1 in crucial cellular pathways has 
been demonstrated and the research of new drugs acting as SIRT1 modulators and relative 
patents exploded [28, 30, 51, 52]. A common intriguing idea is that if SIRT1 acts as a therapeu-
tic target, specific drugs able to activate its signaling might be effective in specific age-related 
pathologies and in cancer. Herein, we resumed and discuss recent scientific data on SIRT1 
modulators (STACs) and their potentiality assessed in vivo, in preclinical rodent models or in 
clinical settings.
3. Resveratrol and its derivatives as sirtuin 1 activators in aging
Since 2006 Sinclair’s team in Harvard University reported that RSV, 3,5,4′-trihydroxystilbene, 
has a therapeutic potential to extend life span by miming caloric restriction to limit metabolic 
alterations in rodents in more than 140 genic pathways [23, 53]. RSV was added to the rodent 
diet at concentrations similar to human use (5.2 and 22.4 mg/kg/day) for 6 months. RSV was 
firstly isolated in late 1930s in leaves of white hellebore Veratrum grandiflorum and character-
ized as a phytoalexin [54], but later in 1990s, it was found in red wine and grapevines [55], 
in traditional herbs in Asia [56–58] in response to adverse conditions, in over 70 different 
plants and fruits like blueberry, raspberry, and mulberry [59]. Its first function was to reduce 
Figure 1. Sirtuin 1 deacetylase activity and its downstream substrates involved in longevity. The red square indicates 
the inhibited pathways and the green square the activated pathways. Stars indicate acetyl groups; (AMPK): 5′ AMP-
activated protein kinase; (eNOS): endothelial nitric oxide synthase; (FOXO1/3): forkhead box protein O 1/3; (NAM): 
nicotinamide; (NAD+): nicotinamide dinucleotide; (NAMPT): nicotinamide phosphoribosyltransferase; (NF-kB): nuclear 
factor k B; (p53): protein 53; (PGC1α): peroxisome proliferatoractivated receptor G coactivator 1α; (mTOR): mammalian 
target of rapamycin.
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inflammation and to limit oxidant damage in cardiovascular diseases, the so-called “French 
paradox.” Intriguingly, the use of a glass of red wine reduced the extent of platelet aggre-
gation and cardiovascular side effects in French people despite a high fat diet as reviewed 
in [60]. However, RSV is a photosensitive molecule, chemically composed by two aromatic 
rings linked by a methylene bridge, existing in two isomeric configurations, called trans-RSV 
and cis-RSV (Figure 2). Intriguingly, the most beneficial therapeutic properties are linked to 
trans-RSV even if, when exposed to light and high temperature, more than 80% of trans-RSV 
changes into cis-RSV with low solubility and stability [61].
Nevertheless, it has been calculated that more than 110 glasses of wine should be drunk to 
achieve an anticancer effect in humans [62]. Unfortunately, lipophilicity of RSV conditioned 
its bioavailability, low intestinal absorption, and rapid clearance from the plasma, making 
necessary a high dosage in preclinical and clinical trials [63, 64]. In humans, RSV was admin-
istered as a dose of 25 mg, then grew in the range from 25 to 1000 mg, up to 5 g daily for 
almost 1 month still well tolerated [65]. However, when administered in healthy volunteers in 
the morning, RSV bioavailability and pharmacokinetic ameliorated [66] and tolerability was 
maintained if associated with other drugs, like quercetin and alcohol [67]. To ameliorate half-
life in the plasma, a modified version of RSV was produced, called Longevinex, able to prevent 
isomerization from trans to cis and it is rich of vitamin D3 (at a dose 1200 IU) and quercetin 
very effective in the metabolic syndrome [68] and cardiac health in mice [69]. Interestingly, 
also in humans, RSV mimicked caloric restriction [70] and attenuated obesogenic changes in 
the metabolic syndrome but had no effects under normal weight patients [71]. Herein, the 
RSV ability to sustain SIRT1 expression/activity is effective when the deacetylase is scarce, 
but unnecessary if SIRT1 level/activity is normal like in postmenopausal women with nor-
mal glucose tolerance or in slightly obese men and women (trans-RSV was taken at a dose 
150 mg daily for 4 weeks) [72]. However, despite extensive data on efficacy of RSV in rodent 
preclinical trials, actually its beneficial role in humans is still debated, greatly depending 
Figure 2. Resveratrol, 3′,5, 4′-trihydroxystilbene, isomers adapted from Nawaz et al. [78].
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from doses and time of administration [73]. Antiaging properties of RSV via SIRT1 and mito-
chondrial health are addressed on amelioration of oxidative metabolism in crucial organs 
like heart and vessels, muscles, kidney but the mechanism is strictly cell-dependent [74–76]. 
Remarkably, at high doses, RSV has been reported to induce mild toxicity in humans where 
somnolence, headache, rash, and myalgia occurred [77]. Herein, to overcome these problems, 
in the past few years, different RSV derivatives have been synthesized ex novo by substituting 
hydroxyl with methoxy groups, so enhancing lipophilicity, or by adding a 4-hydroxy group 
in trans-RSV or a halogen group to potentiate the therapeutic efficacy [78], although differ-
ent promising antimicrobial, antioxidant, and cardioprotective effects have been obtained in 
vitro. Moreover, to improve oral bioavailability of RSV-specific complexes with liposomes, 
lipid or synthetic nanoparticles have been made, even if they resulted with low therapeutic 
potential [79, 80]. In respiratory diseases reproduced in rodent like pulmonary hyperten-
sion, RSV ameliorates asthma and fibrosis via SIRT1 activation [81, 82] and also its deriva-
tive, trimethoxystilbene, demonstrated antioxidant and anti-inflammatory properties in rats 
exposed to hypoxia [83]. Recently, Bastin and Djouadi [84] reviewed RSV potentiality against 
mitochondrial damage and myopathies, and promising results in an animal model of a fatal 
genetic disease called Duchenne muscular dystrophy were reported. In dystrophic mice (mdx 
model), RSV supplementation (0.5% in the diet for 3 weeks) ameliorated muscle atrophy and 
prevented sciatic denervation signaling [85]. However, caution must be taken to extrapolate 
successful data obtained in animal models to humans where RSV might modulate different 
pathways in a dose-dependent manner. Autoimmune diseases represent an emerging type of 
chronic diseases often associated to aging that affect specific or multiple organs at the same 
time like rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, 
and type I diabetes [86]. RSV inhibited transcription factors crucial in autoinflammation, 
like nuclear factor k B (NF-kB) [87], and curiously in these pathologies, stopped SIRT1 activ-
ity. Intriguingly, RSV behaves as a potent drug mainly in animal models, although actually 
poor patient outcome and reduced number of clinical trials made necessary further stud-
ies in humans to exclude side effects or competition with other drugs [88]. RSV has been 
tested successfully in neuronal inflammation, psychotic mice (up to 30 mg/kg/daily) [89, 90], 
depressed menopausal women (orally 25 mg/day for 12 weeks) [91], and in patients with 
minimal hepatic encephalopathy, a frequent complication of cirrhosis [92]. However, the oral 
dosing of RSV seemed to cross the blood-brain barrier but more potent polyphenols specifi-
cally addressed on brain with promising preventive and not only therapeutic properties are 
under research [93]. Moreover, RSV administered 48 h prior the induction of a subarachnoid 
hemorrhage activated SIRT1 thereby reducing mortality and improving neurological func-
tions in rats [94]. Pterostilbene is a natural phenolic drug found in sandalwood and some 
fruits like grapes and blueberries that ameliorated neuronal aging and memory deficit in rats 
[95]. Chemically, it is a dimethylether analogue of RSV with better pharmacokinetic and oral 
bioavailability in rats (80% in comparison to 20% RSV) [96]. Recently, pterostilbene demon-
strated better efficacy than RSV in the modulation of behavior and functional improving in 
SAMP8 mouse, a rodent model of accelerated aging validated to study Alzheimer’s disease 
[97]. Moreover, recent evidences indicated that pterostilbene worked well as cardioprotec-
tive and anti-inflammatory drug in rodents with ischemia-reperfusion [98]. However, both 
pterostilbene and RSV efficacy on aging and longevity have been reviewed recently by Li 
et al. [99], but conclusive data are lacking due to poor water solubility, low bioavailability, 
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and rapid elimination (half-life only 9 h in humans), the main obstacles to work in clinical tri-
als. However, different strategies have been also undertaken to optimize the delivery of RSV 
to strengthen its clinical utility: one strategy was to complex it to controlled release devices, 
another avenue was to use micronized powder (called SRT501) [100]. A crucial year in the 
history of RSV pharmacology was 1997 when Jang et al. [101] firstly reported an antitumoral 
effect in vitro and in vivo in a murine model of skin cancer. However, SIRT1 played a double 
opposite role in cancer linked to severity grade. Indeed, in early cancer phases, when cellular 
mutations are scarce, to activate SIRT1 is a good strategy, but in advanced stages with many 
mutations, SIRT1 may potentiate and accelerate oncogenesis, as demonstrated in breast cancer 
[102]. Remarkably, Li et al. [103] provided evidences that dietary RSV for 4–5 weeks reduced 
prostate neoplastic lesions by about 50% in mice through SIRT1-mediated autophagy. More 
recently in chondrosarcoma cells, xenografted in mice, RSV via SIRT1 stimulated apoptosis 
and decreased tumor growth [104].
4. Synthetic sirtuin 1 activators (STACs) in aging
RSV and natural polyphenols, like quercetin and butein, have been included into the first gener-
ation of SIRT1 activators (STACs). However, to overcome limitations in RSV pharmacology, its 
aspecific interaction with several sirtuins like human sirtuin 5 and the competition with SIRT1 
for the catalytic site [105], Sinclair laboratory since 2000s produced novel synthetic STACs [28] 
to fight aging-associated disabilities. The screening of potential STACS began in vitro looking 
for more than 18,000 drugs and resulted in 21 compounds able to stimulate the catalytic site 
in SIRT1 deacetylase enzyme [106]. Using a fluorescence polarization assay verified by mass 
spectrometry, novel synthetic STACs were obtained but a strong scientific controversy occurred 
on the efficacy of different drugs on SIRT1 activation. To date, the research on synthetic STACs 
(came to the fifth generation) has produced more soluble and specific compounds [30] with an 
in vitro 1000-fold greater potency than RSV to mimic calorie restriction. Intriguingly, STACs 
extended life span in obese mice [107] but also in mice fed a standard diet. [108]. Interestingly, 
SRT2104 was able to preserve muscle mass, strength, and bone integrity in muscle-atrophy 
induced by hind limb suspension and fasting [109]. Moreover, also SRT1720 behaved as an 
effective SIRT1 agonist in vivo in two independent rodent models of osteoporosis, where after 
1 month or 3 months of oral treatment, femoral bone mass grew about 30% [110]. These stud-
ies have great translational implications considering the high frequency of fractures in human 
osteoporosis. Oral administration of SRT3025 (50 or 100 mg/kg/day) for 6 weeks, starting 
6 weeks after ovariectomy, successfully reversed scarcity of bone mass and osteoporosis in mice 
[111]. Remarkably, SRT1720 intraperitoneally injected daily in female obese mice for 6 weeks 
improved the vitality of follicles via sustained SIRT1 able to reduce atresia and the abnormal 
primordial follicles activation [112]. In human plasmacytoma xenografted mice, a model 
utilized to validate new therapies against multiple myeloma, oral treatment with SRT1720 
(200 mg/kg) on five consecutive days/week schedule for 4 weeks reduced tumor growth in 
combination with other drugs, like bortezomib, potentiated antimyeloma effects [113]. Several 
STACS have been tested as SIRT1 modulators in preclinical rodent model to fight diabetes, 
obesity, neurodegeneration, atherosclerosis, bone and muscle mass [114], and most relevant 
diseases investigated in the preclinical trials have been resumed in Figure 3.
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Later, since 2012, an STAC phase I clinical trials started in humans [115]. SRT2104 in doses 
ranged from 0.03 to 3 g was well tolerated with a bioavailability about 14% in male and female 
volunteers. Remarkably, the same drug was also tested in elderly volunteers with no side 
effects [116]. In these last years, various human clinical trials with STACs have been started 
but to date the only ended with SRT2104 in patients with moderate to severe psoriasis demon-
strated a promising efficacy [117]. Despite some encouraging evidences, in other clinical trials, 
SRT2104 administration for 28 days to diabetic patients (n = 15) was ineffective on insulin 
resistance and endothelial function but induced a striking weight reduction not observed in 
placebo [118]. Moreover, patients with mild to moderate ulcerative colitis were treated with 
SRT2104 at 50–500 mg daily for 8 weeks, and they not presented any clinical remission so the 
clinical trials stopped [119]. However, the times are ripe to start further clinical trials and to 
test novel STACs for longer times, hoping in new exciting results.
5. Recommendation
RSV, the main member of the first generation STACs, is not found in meat or dairy but is present 
in vegetables and herbs. Renisalo et al. [120] have indicated main sources of RSV in vegetables 
and seeds like cocoa, grape, hop, peanuts, pistachios, tomato, and berries. However, RSV is also 
present in common Asian herbs like Polygonum cuspidatum, known as Japanese knotweed. Its 
dried roots have been infused to produce “Itadori” tea, which means “well-being” in Japanese, 
a folk beverage largely used for the treatment of heart disease and stroke [59].
To date, pleiotropic effects of trans-RSV in degenerative and metabolic diseases in elderly 
are recognized, but despite a lot of evidences in vitro and in rodent model, their therapeutic 
role in humans is still debated. Firstly, its beneficial effect is strictly dose-dependent, and 
to potentiate mitochondria health, it is required at least an oral dose of RSV of 1 g/day in 
Alzheimer’s patients and generally from 0.5 g up to 5 g/day to reach a therapeutic level in 
plasma (5 μM) [121]. Furthermore, RSV efficacy is also time-dependent, and an oral daily 
intake for 2 months is effective in patients with angina pectoris only if trans-RSV (at 20 mg) is 
Figure 3. Synthetic SIRT1 activators (STACs) effective in rodent models.
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associated with calcium fructoborate [122]. Moreover, controversial RSV effects reported on 
nonalcoholic fatty liver (NAFLD) are probably linked to different oral doses (from 500 mg/
day up to 3000 mg/day), time of administration (from 56 days up to 6 months), and number 
of patients considered in clinical trials [123]. On the contrary, promising results have been 
recently obtained on 119 patients with mild to moderate Alzheimer’s disease orally supple-
mented with RSV at 1 g twice a day for 52 weeks, which presented reduced inflammatory 
markers in plasma and cerebrospinal fluid [124]. Herein, there is still a lot of research to do on 
the RSV and other STACs drug and caution must be taken to sustain their definitive clinical 
therapeutic effects in humans.
6. Conclusions
A constant effort has been made to synthesize novel drugs to extend life span, to prolong the 
quality of the life in elderly, and to limit age-associated diseases. Unfortunately, to date, there 
is no drug that could be an elixir of longevity for humans even if more than a hundred clinical 
trials on natural or synthetic SIRT1 activators are ongoing worldwide. However, there are still 
many challenges to discover and test the efficacy of antiaging drugs in clinics together with the 
necessity to get funds for a long time. The main final message from this chapter may be that a big 
scientific awareness is placed in the aging research, as indicated by the tremendous number of 
published articles on this topic. Indeed, all actors in the biogerontology scenario agree that not 
only the extension of the life is important in elderly, but it is fundamental its quality, maintaining 
a good health. To reach this aim, dietary intervention with caloric restriction mimetics is crucial, 
but remember to start early during adult age to best adapt your metabolism to counteract aging.
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